文献速递呼吸道感染

新型内体NOX2氧化酶抑制剂减轻大流行甲型流感病毒诱导的小鼠肺部炎症

Novel endosomal NOX2 oxidase inhibitor ameliorates pandemic influenza A virus-induced lung inflammation in mice.
PubMed 文献 · Respirology · 2019-03-18

本研究在高致病性PR8甲型流感病毒感染C57Bl/6小鼠模型中,于感染前1天鼻内给予内体靶向NOX2氧化酶抑制剂Cgp91ds-TAT(0.2 mg/kg/day)或2% DMSO溶剂对照,感染后第3天评估气道与肺部炎症、病毒滴度及ROS生成。结果显示Cgp91ds-TAT显著减轻气道炎症(包括中性粒细胞浸润)、肺泡炎程度和炎症细胞ROS生成,并显著增强肺部病毒mRNA清除。结论提示内体NOX2氧化酶促进IAV感染致病性肺部炎症,其局部抑制剂是潜在治疗策略。

要点

  • 内体NOX2氧化酶抑制剂Cgp91ds-TAT可减轻高致病性PR8流感病毒诱导的小鼠气道炎症和肺泡炎。
  • 该治疗显著减少炎症细胞ROS生成并增强肺部病毒mRNA清除。
  • 内体靶向NOX2氧化酶抑制是应对流感大流行的潜在新型治疗策略。

核心结论

  • 内体NOX2氧化酶促进甲型流感病毒感染所致致病性肺部炎症。
  • 内体NOX2氧化酶抑制剂的局部递送是抗IAV的新型治疗策略,有望限制流行和大流行期间的致病性。

研究设计与样本

  • C57Bl/6小鼠于感染前1天鼻内给予2% DMSO溶剂对照或Cgp91ds-TAT(0.2 mg/kg/day)。
  • 随后以高致病性PR8 IAV株(500 PFU/mouse)感染,感染后第3天处死小鼠评估气道与肺部炎症、病毒滴度和ROS生成。

主要发现

  • PR8感染引起明显气道炎症、上皮剥脱、肺泡炎和炎症细胞ROS产生。
  • Cgp91ds-TAT治疗显著减轻气道炎症(包括中性粒细胞浸润)、肺泡炎程度和炎症细胞ROS生成。
  • Cgp91ds-TAT抗炎表型显著增强PR8感染后肺部病毒mRNA清除。

临床怎么用

  • 提示内体NOX2氧化酶可作为甲型流感病毒感染相关肺部炎症的潜在治疗靶点。
  • 内体靶向NOX2氧化酶抑制剂的局部递送策略值得进一步临床前和临床研究。

局限性

  • 研究为小鼠模型,结果向人体外推需谨慎。
  • 仅评估感染后第3天单一时间点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Influenza A viruses (IAV) cause respiratory tract infections that can be fatal when the virus spreads to the alveolar space (i.e. alveolitis), and this is mainly observed with highly pathogenic strains. Reactive oxygen species (ROS) production by the NOX2 NADPH oxidase in endosomes has been directly implicated in IAV pathology. Recently, we demonstrated that treatment with a novel endosome-targeted NOX2 oxidase inhibitor, cholestanol-conjugated gp91dsTAT (Cgp91ds-TAT), attenuated airway inflammation and viral replication to infection with a low pathogenic influenza A viral strain. Here, we determined whether suppression of endosome NOX2 oxidase prevents the lung inflammation following infection with a highly pathogenic IAV strain. METHODS: C57Bl/6 mice were intranasally treated with either DMSO vehicle (2%) or Cgp91ds-TAT (0.2 mg/kg/day) 1 day prior to infection with the high pathogenicity PR8 IAV strain (500 PFU/mouse). At Day 3 post-infection, mice were culled for the evaluation of airway and lung inflammation, viral titres and ROS generation. RESULTS: PR8 infection resulted in a marked degree of airway inflammation, epithelial denudation, alveolitis and inflammatory cell ROS production. Cgp91ds-TAT treatment significantly attenuated airway inflammation, including neutrophil influx, the degree of alveolitis and inflammatory cell ROS generation. Importantly, the anti-inflammatory phenotype affected by Cgp91ds-TAT significantly enhanced the clearance of lung viral mRNA following PR8 infection. CONCLUSION: Endosomal NOX2 oxidase promotes pathogenic lung inflammation to IAV infection. The localized delivery of endosomal NOX2 oxidase inhibitors is a novel therapeutic strategy against IAV, which has the potential to limit the pathogenesis caused during epidemics and pandemics.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. To EE, Luong R, Diao J, et al. Novel endosomal NOX2 oxidase inhibitor ameliorates pandemic influenza A virus-induced lung inflammation in mice. Respirology. 2019. PMID: 30884042. doi:10.1111/resp.13524

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。